Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: A pilot study

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 6, 2015, Pages 272-280

  Connett, Gary J ^a   Pike, Katharine C ^b   Legg, Julian P ^b   Cathie, Katrina ^c   Dewar, Ann ^d   Foote, Keith ^e   Harris, Amanda ^b   Faust, Saul N ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e Hampshire Hospitals NHS Trust   (United Kingdom)

Author keywords

ciprofloxacin; cystic fibrosis; Pseudomonas aeruginosa; randomized controlled trial

Indexed keywords

CIPROFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT;

ADOLESCENT; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; UPPER RESPIRATORY TRACT INFECTION; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; ENGLAND; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS DISEASES;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; ENGLAND; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PILOT PROJECTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 84947236408     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815601571     Document Type: Article

References (24)

1. Abman S. Ogle J. Butler-Simon N. (1988) Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113: 826–830.
2. Avadhanula V. Rodriguez C. Devincenzo J. Wang Y. Webby R. (2006) Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol 80: 1629–1636.
3. Bland M. (2000) An Introduction to Statistics. Oxford: Oxford University Press.
4. Collinson J. Nicholson K. Cancio E. Ashman J. Ireland D. Hammersley V. (1996) Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 51: 1115–1122.
5. De Vrankrijker A. Wolfs T. Ciofu O. Hoiby N. van der Ent C. Poulsen S. (2009) Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol 81: 2096–2103.
6. Gibson R. Emerson J. Mayer-Hamblett N. Burns J. McNamara S. Accurso F. (2007) Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 42: 610–623.
7. Johansen H. Hoiby N. (1992) Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 47: 109–111.
8. Koehler D. Downey G. Sweezey N. Tanswell A. Hu J. (2004) Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 31: 377–381.
9. Kosorok M. Zeng L. West S. Rock M. Splaingard M. Laxova A. (2001) Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32: 277–287.
10. Langton Hewer S. Smyth A. (2009) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 4: CD004197.:
11. Lee T. Brownlee K. Conway S. Denton M. Littlewood J. (2003) Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cystic Fibrosis 2: 29–34.
12. Ortiz J. Neuzil K. Victor J. Wald A. Aitken M. Goss C. (2010) Influenza associated cystic fibrosis pulmonary exacerbations. Chest 137: 852–860.
13. Ramphal R. Small P. Shands J. Jr. Fischlschweiger W. Small P. Jr. (1990) Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation. Infect Immunol 27: 614–619.
14. Ramsey B. Gore E. Smith A. Cooney M. Redding G. Foy H. (1989) The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child 143: 662–668.
15. Rogers G. Hart C. Mason J. Hughes M. Walshaw M. Bruce K. (2003) Bacterial diversity in cystic fibrosis lung infections 16S rDNA length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol 41: 3548–3558.
16. Schulz K. Altman D. Moher D. for the CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 340: c332.
17. Smyth A. Smyth R. Tong C. Hart C. Heaf D. (1995) Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 73: 117–120.
18. Spilker T. Coenye T. Vandamme P. LiPuma J. (2004) PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J Clin Microbiol 42: 2074–2079.
19. Taccetti G. Bianchini E. Cariani L. Buzzetti R. Costantini D. Trevisan F. (2012) Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols Thorax 67: 853–859.
20. Tramper-Stranders G. Wolfs T. van Haren Noman S. van Aalderen W. Nagelkerke A. Nuijsink M. (2010) Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 65: 915–920.
21. Van Ewijk B. Wolfs T. Aerts P. van Kessel K. Fleer A. Kimpen J. (2007) RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 61: 398–403.
22. Van Ewijk B. Wolfs T. Fleer A. Kimpen J. van der Ent C. (2006) High Pseudomonas aeruginosa acquisition rate in CF. Thorax 61: 641–642.
23. Wagener J. Rasouliyan L. VanDevanter D. Pasts D. Regelmann W. Morgan W. (2013) Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 48: 666–673.
24. Wainwright C. Vidmar S. Armstrong D. Byrnes C. Carlin J. Cheney J. (2011) Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 306: 163–171.